AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical
BioSpace
In AstraZeneca's third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered sympt
pharminent
July 8, 2026 (Last updated: July 10, 2026)
BioSpace
In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered sympt
